Global Markets for Emerging Insulin Drug and Delivery Technologies: Focus on Syringes and Vials
상품코드:1441931
리서치사:BCC Research
발행일:2024년 02월
페이지 정보:영문 158 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 신규 인슐린 제제 및 전달 기술 시장 규모는 2023년 558억 달러에서 성, 예측 기간 중 9.8%의 CAGR로 추이하며, 2028년말에는 889억 달러 규모로 성장할 것으로 예측됩니다.
인슐린 시린지 및 바이알 시장은 2023년 243억 달러에서 같은 기간 중 8.7%의 CAGR로 추이하며, 2028년말에는 370억 달러 규모로 성장할 것으로 예측됩니다. 또한 스마트 인슐린 펜 시장 규모는 2023년 42억 달러에서 12.6%의 CAGR로 추이하며, 2028년말에는 77억 달러 규모로 성장할 것으로 예측됩니다.
세계의 신규 인슐린 제제 및 전달 기술의 시장을 조사했으며, 시장 및 질환의 배경, 시장 영향요인 및 시장 기회의 분석, 시장 규모의 추이·예측, 각종 구분·지역별 상세 분석, 기술·특허의 동향, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 서론
제2장 요약·하이라이트
시장 전망
시장 개요
개발과 동향
제3장 시장 개요
당뇨병이란?
당뇨병의 유형
1형 당뇨병
2형 당뇨병
임신 당뇨병 또는 임신중 고혈당
내당능장애와 공복시 혈당 장애
당뇨병의 역학
성별 분포
지역 격차
시장 역학 스냅숏
시장에 영향을 미치는 요인
시장 촉진요인
시장 억제요인
제4장 세계의 신규 인슐린 제제 및 전달 기술 시장 : 유형별
개요
인슐린 시린지의 기술적 진보
인슐린 전달 펜형 디바이스
일회용 인슐린 펜
재사용 가능 인슐린 펜
인슐린 제제 및 전달 펜형 디바이스의 기술적 진보
외부 인슐린 펌프
인슐린 펌프 시스템의 기술적 진보
삽입형 인슐린 펌프
클로즈드 루프 인공 췌장
바이오닉 췌장
스마트 펜
제5장 세계의 신규 인슐린 제제 및 전달 디바이스 시장 : 용도별
개요
1형 당뇨병
2형 당뇨병
임신 당뇨병
제6장 세계의 인슐린 제제 및 전달 디바이스 시장 : 지역별
개요
북미
유럽
아시아태평양
기타 지역
제7장 규제 상황
개요
미국
유럽
일본
중국
제8장 인슐린 제제 및 전달 시장의 지속가능성 : ESG 관점
ESG 퍼포먼스 분석
제9장 신규 기술
혈당 제어를 초월한 환자 결과
제10장 특허 분석
제11장 M&A와 벤처 자금조달 전망
M&A 분석
제12장 경쟁 구도
개요
제13장 기업 개요
ASTRAZENECA
B. BRAUN SE
BD
CARDINAL HEALTH
DEBIOTECH SA
DIABELOOP SA
EMPERRA GMBH E-HEALTH TECHNOLOGIES
EMBECTA CORP.
F. HOFFMANN-LA ROCHE LTD.
INSULET CORP.
JOHNSON & JOHNSON SERVICES INC.
LIFESCAN IP HOLDINGS LLC.
LILLY
MEDTRONIC
NOVO NORDISK A/S
NUGEN MEDICAL DEVICES
OWEN MUMFORD LTD.
SANOFI
SOOIL DEVELOPMENTS CO. LTD.
TANDEM DIABETES CARE INC.
TERUMO CORP.
YPSOMED AG
제14장 부록
KSA
영문 목차
영문목차
The global market for emerging insulin drug delivery devices is expected to grow from $55.8 billion in 2023 and projected to reach $88.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.8% from 2023 through 2028.
The global market for insulin syringes and vials is expected to grow from $24.3 billion in 2023 and projected to reach $37.0 billion by the end of 2028, at a CAGR of 8.7% from 2023 through 2028.
The global market for smart insulin pens is expected to grow from $4.2 billion in 2023 and projected to reach $7.7 billion by the end of 2028, at a CAGR of 12.6% from 2023 through 2028.
Report Scope:
This report discusses the implications of the growing diabetes epidemic on the global and regional markets for emerging insulin drug and delivery technologies. It discusses companies in the relevant pharmaceutical and medical industries and provides profiles of the leading players as well as an update on M&A activity. The report's patent analysis focuses on developments in Japan, Europe and the U.S. Five-year global sales forecasts are provided for the major categories of insulin drug and delivery technologies and devices categories.
This report segments the global market into four regions -
North America.
Europe.
Asia-Pacific.
Rest of the World (RoW).
Report Includes:
57 data tables and 83 additional tables
An overview and industry analysis of the global markets for emerging insulin drug and delivery technologies, with an emphasis on plastic insulin syringes and vials
Analyses of the global market trends, with historical market revenue data (sales figures) for 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Estimate of the actual market size and revenue growth forecast, and a corresponding market share analysis by product type, application and region
A look at the emerging technologies that have potential in the diabetes market, with improved glucose control, along with improved delivery methods
Examination of the current state of the insulin drug and delivery industry structure, focusing on technological updates and issues surrounding insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios
Discussion of market dynamics, clinical trial applications, regulations, and penetration of technologies in the pharmaceutical and biotechnology markets
Discussion of the ESG developments and how they impact corporate performance, ratings and matrices and consumer attitude, as well as the ESG practices of leading pharma and biotech companies
Review of the key patent grants/publications for insulin as a drug, along with its delivery methods
Analysis of the competitive landscape based on recent developments and segmental revenues of leading companies
Profiles of the leading market players
Table of Contents
Chapter 1 Introduction
Overview
Study Goals and Objectives
Reasons for Doing the Study
What's New in this Report?
Scope of Report
Information Sources
Methodology
Secondary Research
Geographic Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Market Summary
Developments and Trends
Chapter 3 Market Overview
Introduction
What is Diabetes?
Types of Diabetes
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes Mellitus or Hyperglycemia in Pregnancy
Impaired Glucose Tolerance and Impaired Fasting Glucose
Epidemiology of Diabetes
Gender Distribution
Regional Disparities
Market Dynamics Snapshot
Factors Affecting the Market
Market Drivers
Market Restraints
Chapter 4 Global Market for Emerging Insulin Drug and Delivery Technologies, by Type
Overview
Technological Advances in Insulin Syringes
Insulin Delivery Pen Devices
Disposable Insulin Pens
Reusable Insulin Pens
Technological Advances in Insulin Drug and Delivery Pen Devices
External Insulin Pumps
Technological Advances in Insulin Pump Systems
Implantable Insulin Pumps
Closed-Loop Artificial Pancreas
Bionic Pancreas
Smart Pens
Chapter 5 Global Market for Emerging Insulin Drug Delivery Devices, by Application
Overview
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Chapter 6 Global Market for for Insulin Drug Delivery Devices, by Region
Overview
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Regulatory Landscape
Overview
U.S. Regulations for Insulin Drug and Delivery Technologies
European Regulations for Insulin Drug and Delivery Technologies
Japan's Regulations for Insulin Drug and Delivery Technologies
China's Regulations for Insulin Drug and Delivery Technologies
Chapter 8 Sustainability in the Insulin Drug and Delivery Market: An ESG Perspective
Introduction
ESG Performance Analysis
Chapter 9 Emerging Technologies
Introduction
Patient Outcomes Beyond Glucose Control
Chapter 10 Patent Analysis
Overview
Chapter 11 M&A and Venture Funding Outlook
M&A Analysis
Chapter 12 Competitive Landscape
Overview
Chapter 13 Company Profiles
ASTRAZENECA
B. BRAUN SE
BD
CARDINAL HEALTH
DEBIOTECH SA
DIABELOOP SA
EMPERRA GMBH E-HEALTH TECHNOLOGIES
EMBECTA CORP.
F. HOFFMANN-LA ROCHE LTD.
INSULET CORP.
JOHNSON & JOHNSON SERVICES INC.
LIFESCAN IP HOLDINGS LLC.
LILLY
MEDTRONIC
NOVO NORDISK A/S
NUGEN MEDICAL DEVICES
OWEN MUMFORD LTD.
SANOFI
SOOIL DEVELOPMENTS CO. LTD.
TANDEM DIABETES CARE INC.
TERUMO CORP.
YPSOMED AG
Chapter 14 Appendix
Government Regulatory Agencies and Professional Organizations
